Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;117:2492-2501
Published online before print May 5, 2008, doi: 10.1161/CIRCULATIONAHA.107.756809
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correction
Right arrow All Versions of this Article:
117/19/2492    most recent
CIRCULATIONAHA.107.756809v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Benn, M.
Right arrow Articles by Tybjærg-Hansen, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benn, M.
Right arrow Articles by Tybjærg-Hansen, A.
Related Collections
Right arrow Clinical genetics
Right arrow Genetics of Stroke
Right arrow Epidemiology
Right arrow Genetics of cardiovascular disease

(Circulation. 2008;117:2492-2501.)
© 2008 American Heart Association, Inc.


Genetics

Mitochondrial Haplogroups

Ischemic Cardiovascular Disease, Other Diseases, Mortality, and Longevity in the General Population

Marianne Benn, MD, PhD; Marianne Schwartz, MSc, PhD; Børge G. Nordestgaard, MD, DMSc; Anne Tybjærg-Hansen, MD, DMSc

From the Departments of Clinical Biochemistry (M.B., A.T.-H.) and Clinical Genetics (M.S.), Rigshospitalet, Copenhagen University Hospital; Department of Clinical Biochemistry, Herlev University Hospital (B.G.N.); and the Copenhagen City Heart Study, Bispebjerg University Hospital (B.G.N., A.T.-H.); all Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.

Correspondence to Anne Tybjærg-Hansen, MD, DMSc, Department of Clinical Biochemistry KB3011, Section for Molecular Genetics, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark. E-mail at-h{at}rh.regionh.dk

Received November 30, 2007; accepted February 22, 2008.

Background— Rare mutations in the mitochondrial genome may cause disease. Mitochondrial haplogroups defined by common polymorphisms have been associated with risk of disease and longevity. We tested the hypothesis that common haplogroups predict risk of ischemic cardiovascular disease, morbidity from other causes, mortality, and longevity in a general population of European descent.

Methods and Results— We followed 9254 individuals from the Danish general population, in the Copenhagen City Heart Study, prospectively for risk of ischemic cardiovascular disease, morbidity from other causes, and mortality during 25 and 11 years, respectively. Haplogroup frequencies were as follows: H (45.9%), U (15.9%), T (9.9%), J (9.1), K (6.2%), V (4.5%), W/I (3.8%), and Z (3.5%). Hazard ratios for hospitalization due to all cardiovascular disorders (haplogroup U: 1.0 [95% confidence interval{CI}, 0.9 to 1.1]; T: 0.9 [95% CI, 0.8 to 1.0]; J: 1.0 [95% CI, 0.9 to 1.1]; K: 1.0 [95% CI, 0.9 to 1.2]; V: 1.0 [95% CI, 0.9 to 1.2]; W/I: 0.8 [95% CI, 0.7 to 1.0]; Z: 1.0 [95% CI, 0.8 to 1.2]), ischemic heart disease (U: 0.9 [95% CI, 0.8 to 1.1]; T: 0.9 [95% CI, 0.7 to 1.0]; J: 1.1 [95% CI, 0.9 to 1.2]; K: 1.1 [95% CI, 0.9 to 1.3]; V: 1.1 [95% CI, 0.9 to 1.4]; W/I: 1.1 [95% CI, 0.8 to 1.4]; Z: 1.1 [95% CI, 0.8 to 1.4]), and ischemic cerebrovascular disease (U: 1.1 [95% CI, 0.9 to 1.4]; T: 0.9 [95% CI, 0.7 to 1.2]; J: 1.1 [95% CI, 0.9 to 1.4]; K: 1.0 [95% CI, 0.8 to 1.4]; V: 1.1 [95% CI, 0.8 to 1.5]; W/I: 0.8 [95% CI, 0.5 to 1.3]; Z: 0.9 [95% CI, 0.6 to 1.4]) did not differ from 1.0 for any haplogroup versus the most common haplogroup H. Results were similar for hospitalization due to infectious and parasitic diseases, respiratory infections, respiratory disorders, malignant neoplasms, digestive disorders, musculoskeletal disorders, neuropsychiatric disorders, and miscarriages. Likewise, hazard ratios for death from all causes were not different from 1.0 for any haplogroup versus haplogroup H (U: 1.0 [95% CI, 0.8 to 1.1]; T: 0.9 [95% CI, 0.8 to 1.1]; J: 0.9 [95% CI, 0.8 to 1.1]; K: 1.0 [95% CI, 0.8 to 1.2]; V: 1.1 [95% CI, 0.9 to 1.3]; W/I: 0.8 [95% CI, 0.7 to 1.1]; Z: 0.9 [95% CI, 0.7 to 1.2]). Finally, after stratification by major causes of death, hazard ratios remained insignificant.

Conclusions— Our results do not support an association of mitochondrial haplogroups with risk of ischemic cardiovascular disease, morbidity from other causes, mortality, or longevity in a large general population of European descent.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
Int J EpidemiolHome page
R. S Bhopal and S. B Rafnsson
Could mitochondrial efficiency explain the susceptibility to adiposity, metabolic syndrome, diabetes and cardiovascular diseases in South Asian populations?
Int. J. Epidemiol., August 1, 2009; 38(4): 1072 - 1081.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. D. Michelakis
Mitochondrial Medicine: A New Era in Medicine Opens New Windows and Brings New Challenges
Circulation, May 13, 2008; 117(19): 2431 - 2434.
[Full Text] [PDF]